^
    Back
    Association details:
    Biomarker:MELK overexpression
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen:R-CHOP (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Blood Cancer J
    Title:

    Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma

    Published date:
    11/18/2019
    Excerpt:
    ...high MELK expression levels were associated with a significant worse survival in DLBCL patients (93 ABC-, 108 GCB-, and 32 unclassified DLBCL patients) receiving R-CHOP treatment…
    DOI:
    https://doi.org/10.1038/s41408-019-0249-x